VennVax, a DNA-prime, peptide-boost multi-T-cell epitope poxvirus vaccine, induces protective immunity against vaccinia infection by T cell response alone

Vaccine

Volumn 29, Issue 3, 2011, Pages 501-511

  Moise, Leonard ^a,b   Buller, R Mark ^c   Schriewer, Jill ^c   Lee, Jinhee ^d   Frey, Sharon E ^c   Weiner, David B ^f   Martin, William ^a   De Groot, Anne S ^a,b,e  

^a EpiVax Inc   (United States)

^b UNIVERSITY OF RHODE ISLAND   (United States)

^c SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^e BROWN UNIVERSITY   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Epitope based vaccine; Immunoinformatics; Poxvirus vaccine; T lymphocyte epitopes

Indexed keywords

DNA VACCINE; EPITOPE; PRIMER DNA; UNCLASSIFIED DRUG; VENNVAX;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; BIOINFORMATICS; HLA SYSTEM; HUMORAL IMMUNITY; IMMUNOGENICITY; LYMPHOCYTE ACTIVATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TRANSGENIC MOUSE; VACCINATION; VACCINIA;

ANIMALS; DISEASE MODELS, ANIMAL; EPITOPES, T-LYMPHOCYTE; IMMUNIZATION, SECONDARY; MICE; MICE, TRANSGENIC; SMALLPOX; SMALLPOX VACCINE; SURVIVAL ANALYSIS; T-LYMPHOCYTES; VACCINATION; VACCINES, DNA; VACCINES, SYNTHETIC; VACCINIA;

EID: 78650519402     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.10.064     Document Type: Article

References (42)

1. Jahrling P.B., Fritz E.A., Hensley L.E. Countermeasures to the bioterrorist threat of smallpox. Curr Mol Med 2005, 5(8):817-826.
2. Bremen J.G., Henderson D.A. Poxvirus dilemmas-monkeypox, smallpox, and biologic terrorism. N Engl J Med 1998, 339:556-559.
3. Testimony of Stephen M. Ostroff. March 8, 2000; U.S. House of Representatives Committee on Commerce. National Security, Veterans Affairs, and International Relations. Available at: URL: http://www.bt.cdc.gov/press/ostroff_03082000.asp.
4. Henderson D.A. The looming threat of bioterrorism. Science 1999, 283:1279-1282.
5. Earl P.L., Americo J.L., Wyatt L.S., Espenshade O., Bassler J., Gong K., et al. Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus. Proc Natl Acad Sci USA 2008, 105(31):10889-10894.
6. Kennedy R.B., Ovsyannikova I.G., Jacobson R.M., Poland G.A. The immunology of smallpox vaccines. Curr Opin Immunol 2009, 21(3):314-320.
7. Halsell J.S., Riddle J.R., Atwood J.E., Gardner P., Shope R., Poland G.A., et al. Myopericarditis following smallpox vaccination among vaccinia-naive US military personnel. JAMA 2003, 289(24):3283-3289.
8. Jacobson I.G., Smith T.C., Smith B., Wells T.S., Reed R.J., Ryan M.A. US military service members vaccinated against smallpox in 2003 and 2004 experience a slightly higher risk of hospitalization postvaccination. Vaccine 2008, 26(32):4048-4056.
9. Frey S.E., Newman F.K., Kennedy J.S., Ennis F., Abate G., Hoft D.F., et al. Comparison of the safety and immunogenicity of ACAM1000, ACAM2000 and Dryvax in healthy vaccinia-naive adults. Vaccine 2009, 27(10):1637-1644.
10. Frey S.E., Newman F.K., Kennedy J.S., Sobek V., Ennis F.A., Hill H., et al. Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge. Vaccine 2007, 25(51):8562-8573.
11. Moise L., McMurry J.A., Buus S., Frey S., Martin W.D., De Groot A.S. In silico-accelerated identification of conserved and immunogenic variola/vaccinia T-cell epitopes. Vaccine 2009, 27(46):6471-6479.
12. De Groot A.S., Marcon L., Bishop E.A., Rivera D., Kutzler M., Weiner D.B., et al. HIV vaccine development by computer assisted design: the GAIA vaccine. Vaccine 2005, 23(17-18):2136-2148.
13. Livingston B.D., Newman M., Crimi C., McKinney D., Chesnut R., Sette A. Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines. Vaccine 2001, 19(32):4652-4660.
14. FDA Center for Biologics Evaluation and Research (CBER). Points to Consider on Plasmid DNA Vaccines for Preventive Infectious Diseases Indications (Docket no. 96N-0400).
15. Gursel I., Gursel M., Ishii K.J., Klinman D.M. Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides. J Immunol 2001, 167(6):3324-3328.
16. Kong Y.C., Lomo L.C., Motte R.W., Giraldo A.A., Baisch J., Strauss G., et al. HLA-DRB1 polymorphism determines susceptibility to autoimmune thyroiditis in transgenic mice: definitive association with HLA-DRB1*0301 (DR3) gene. J Exp Med 1996, 184(3):1167-1172.
17. Sundquist M., Wick M.J. TNF-alpha-dependent and -independent maturation of dendritic cells and recruited CD11(int)CD11b(+) cells during oral Salmonella infection. J Immunol 2005, 175(5):3287-3298.
18. Empig C., Kenner J.R., Perret-Gentil M., Youree B.E., Bell E., Chen A., et al. Highly attenuated smallpox vaccine protects rabbits and mice against pathogenic orthopoxvirus challenge. Vaccine 2006, 24(17):3686-3694.
19. Livingston B., Crimi C., Newman M., Higashimoto Y., Appella E., Sidney J., et al. A rational strategy to design multiepitope immunogens based on multiple Th lymphocyte epitopes. J Immunol 2002, 168:5499-5506.
20. Abel K., Strelow L., Yue Y., Eberhardt M.K., Schmidt K.A., Barry P.A. A heterologous DNA prime/protein boost immunization strategy for rhesus cytomegalovirus. Vaccine 2008, 26(47):6013-6025.
21. Liu J., O'Brien K.L., Lynch D.M., Simmons N.L., La Porte A., Riggs A.M., et al. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 2009, 457(7225):87-91.
22. Tanguay S., Killion J.J. Direct comparison of ELISPOT and ELISA-based assays for detection of individual cytokine-secreting cells. Lymphokine Cytokine Res 1994, 13(4):259-263.
23. Mo X.Y., Sarawar S.R., Doherty P.C. Induction of cytokines in mice with parainfluenza pneumonia. J Virol 1995, 69(2):1288-1291.
24. Jing L., Chong T.M., Byrd B., McClurkan C.L., Huang J., Story B.T., et al. Dominance and diversity in the primary human CD4 T cell response to replication-competent vaccinia virus. J Immunol 2007, 178(10):6374-6386.
25. Jing L., Davies D.H., Chong T.M., Chun S., McClurkan C.L., Huang J., et al. An extremely diverse CD4 response to vaccinia virus in humans is revealed by proteome-wide T-cell profiling. J Virol 2008, 82(14):7120-7134.
26. Calvo-Calle J.M., Strug I., Nastke M.D., Baker S.P., Stern L.J. Human CD4+ T cell epitopes from vaccinia virus induced by vaccination or infection. PLoS Pathog 2007, 3(10):1511-1529.
27. Moutaftsi M., Peters B., Pasquetto V., Tscharke D.C., Sidney J., Bui H.H., et al. A consensus epitope prediction approach identifies the breadth of murine T(CD8+)-cell responses to vaccinia virus. Nat Biotechnol 2006, 24(7):817-819.
28. Barlow D.J., Edwards M.S., Thornton J.M. Continuous and discontinuous protein antigenic determinants. Nature 1986, 322(6081):747-748.
29. Camacho C.J., Katsumata Y., Ascherman DP Structural and thermodynamic approach to peptide immunogenicity. PLoS Comput Biol 2008, 4(11):e1000231.
30. Panchanathan V., Chaudhri G., Karupiah G. Antiviral protection following immunization correlates with humoral but not cell-mediated immunity. Immunol Cell Biol 2010, (January). [Epub ahead of print].
31. Robbins J.B., Schneerson R., Szu S.C. Hypothesis: how licensed vaccines confer protective immunity. Adv Exp Med Biol 1996, 397:169-182.
32. Moutaftsi M., Salek-Ardakani S., Croft M., Peters B., Sidney J., Grey H., et al. Correlates of protection efficacy induced by vaccinia virus-specific CD8+ T-cell epitopes in the murine intranasal challenge model. Eur J Immunol 2009, 39:717-722.
33. Snyder J.T., Belyakov I.M., Dzutsev A., Lemonnier F., Berzofsky J.A. Protection against lethal vaccinia virus challenge in HLA-A2 transgenic mice by immunization with a single CD8+ T-cell peptide epitope of vaccinia and variola viruses. J Virol 2004, 78:7052-7060.
34. Bevan M.J. Helping the CD8(+) T-cell response. Nat Rev Immunol 2004, 4(August (8)):595-602.
35. Wyatt L.S., Earl P.L., Eller L.A., Moss B. Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. Proc Natl Acad Sci USA 2004, 101(13):4590-4595.
36. Xu R., Johnson A.J., Liggitt D., Bevan M.J. Cellular and humoral immunity against vaccinia virus infection of mice. J Immunol 2004, 172:6265-6271.
37. Parker S., Nuara A., Buller R.M., Schultz D.A. Human monkeypox: an emerging zoonotic disease. Future Microbiol 2007, 2:17-34.
38. Asjö B., Stavang H., Sørensen B., Baksaas I., Nyhus J., Langeland N. Phase I trial of a therapeutic HIV type 1 vaccine, Vacc-4x, in HIV type 1-infected individuals with or without antiretroviral therapy. AIDS Res Hum Retroviruses 2002, 18(18):1357-1365.
39. Kran A.M., Sørensen B., Nyhus J., Sommerfelt M.A., Baksaas I., Bruun J.N., et al. HLA- and dose-dependent immunogenicity of a peptide-based HIV-1 immunotherapy candidate (Vacc-4x). AIDS 2004, 18(14):1875-1883.
40. Pietersz G.A., Pouniotis D.S., Apostolopoulos V. Design of peptide-based vaccines for cancer. Curr Med Chem 2006, 13(14):1591-1607.
41. McMurry J.A., Gregory S.H., Moise L., Rivera D., Buus S., De Groot A.S. Diversity of Francisella tularensis Schu4 antigens recognized by T lymphocytes after natural infections in humans: identification of candidate epitopes for inclusion in a rationally designed tularemia vaccine. Vaccine 2007, 25(16):3179-3191.
42. Gregory S.H., Mott S., Phung J., Lee J., Moise L., McMurry J.A., et al. Epitope-based vaccination against Pneumonic Tularemia. Vaccine 2009, 27(39):5299-5306.